The compound with CAS number 330785-84-7 is a key intermediate in the synthesis of the potent and selective multi-kinase inhibitor **Tivozanib (AV-951)**. Its chemical name is 4-[[(3-Chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-5-pyrimidinecarboxylic acid. This molecule contains a central pyrimidine core substituted with a chiral pyrrolidine ring bearing a hydroxymethyl group, a (3-chloro-4-methoxyphenyl)methylamino moiety, and a carboxylic acid group. Tivozanib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor developed for the treatment of advanced renal cell carcinoma (RCC). This specific intermediate represents a crucial advanced building block in the multi-step synthetic route to the final active pharmaceutical ingredient (API). Its structure incorporates essential pharmacophoric elements required for VEGFR binding and inhibition. The synthesis and purification of this high-purity intermediate are critical steps in ensuring the quality, efficacy, and safety of the final drug product. It is primarily used in pharmaceutical manufacturing and process development for Tivozanib.